INVAライブシグナル | Getagraph.comで利益を最大化

売る 107791 min ago

@ $15.84

発行日: 15 2月 2024 @ 05:17

リターン: -3.22%

前回のシグナル: 2月 15 - 03:26

前回のシグナル: 買う

リターン: 0.54 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:45):

Stats
本日の出来高	85 273.00
平均出来高	701 717
時価総額	969.27M
EPS	$0 ( 2024-02-27 )
次の収益日	( $0.170 ) 2024-05-07
Last Dividend	$0.250 ( 2015-09-08 )
Next Dividend	$0 ( N/A )
P/E	6.97
ATR14	$0.00600 (0.04%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Basso Stephen	Buy	25 899	Non-statutory Stock Option
2024-03-05	Basso Stephen	Buy	12 096	Common Stock
2024-03-05	Ronsheim Matthew	Buy	27 338	Non-statutory Stock Option
2024-03-05	Ronsheim Matthew	Buy	12 768	Common Stock
2024-03-05	Zhen Marianne	Buy	23 022	Non-statutory Stock Option

INSIDER POWER
89.73
Last 96 transactions
Buy: 2 118 652 \| Sell: 32 343 813

ボリューム相関

長: 0.01 (neutral)

短: -0.46 (neutral)

Signal:(64.183) Neutral

Innoviva Inc 相関

10 最も正の相関
ESSA	0.92
ONEM	0.92
NAKD	0.911
AADI	0.909
AROW	0.908
DSWL	0.906
CMLS	0.906
AZTA	0.905
BSRR	0.904
UK	0.902

10 最も負の相関
NEO	-0.927
TMDX	-0.919
XLRN	-0.916
MORF	-0.916
HAPP	-0.915
SVC	-0.914
ACVA	-0.913
SGTX	-0.911
MHUA	-0.909
SJ	-0.909

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Innoviva Inc 相関 - 通貨/商品

0.19
( neutral )

0.34
( neutral )

0.00
( neutral )

0.74
( moderate )

-0.74
( moderate negative )

-0.86
( strong negative )

Innoviva Inc 財務諸表

Annual	2023
収益:	$324.26M
総利益:	$245.92M (75.84 %)
EPS:	$-1.910

FY	2023
収益:	$324.26M
総利益:	$245.92M (75.84 %)
EPS:	$-1.910

FY	2022
収益:	$331.34M
総利益:	$317.55M (95.84 %)
EPS:	$-1.080

FY	2021
収益:	$391.87M
総利益:	$0.00 (0.00 %)
EPS:	$2.62

Financial Reports:

No articles found.

Innoviva Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Innoviva Inc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.08 - Potential for dividend initiation, but uncertain (1.64%)

Information

First Dividend	$0.250	2014-08-26
Last Dividend	$0.250	2015-09-08
Next Dividend	$0	N/A
Payout Date	2015-09-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	3.98	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.08
Div. Directional Score	8.09	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

3.98

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2014	$0.500	1.84%
2015	$0.750	5.65%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.573	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.145	1.200	5.18	6.22	[0 - 0.3]
returnOnEquityTTM	0.297	1.500	7.81	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.03	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	5.07	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.360	-1.500	4.00	-6.00	[0 - 0.6]
interestCoverageTTM	9.70	1.000	7.52	7.52	[3 - 30]
operatingCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.21	2.00	8.90	10.00	[0 - 20]
debtEquityRatioTTM	0.663	-1.500	7.35	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.832	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.592	1.000	0.162	0.162	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.315	1.000	9.36	9.36	[0.2 - 2]
assetTurnoverTTM	0.252	0.800	-1.650	-1.320	[0.5 - 2]
Total Score				11.10

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	5.41	1.000	9.55	0	[1 - 100]
returnOnEquityTTM	0.297	2.50	8.59	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.21	2.00	9.26	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.531	1.500	9.79	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.449	1.000	1.265	0	[0.1 - 0.5]
Total Score				5.08

Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.